Start Your Search
P1.02 - Poster Session/ Treatment of Localized Disease – NSCLC (ID 209)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Localized Disease - NSCLC
- Presentations: 1
- Coordinates: 9/07/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
P1.02-032 - Randomized Feasibility Study of S-1 for Adjuvant Chemotherapy in Completely-Resected Stage IA Non-Small-Cell Lung Cancer (SLCG 0701) (ID 754)
09:30 - 17:00 | Author(s): K. Kataoka
The aim of this multicenter study (the Setouchi Lung Cancer Group Study 0701) was to determine the feasible administration schedule of S-1, an oral fluoropyrimidine, for adjuvant chemotherapy in patients with completely-resected pathological stage IA (tumor diameter, 2 to 3 cm) non-small-cell lung cancer (NSCLC).
Patients were randomly assigned to receive an adjuvant chemotherapy of either 4-week oral administration of S-1 (80 mg/m2/day) followed by 2-week rest (group A), or 2-week oral administration of S-1 (80 mg/m2/day) followed by one week rest (Group B). The duration of adjuvant chemotherapy was one year in both arms. The primary endpoint was feasibility.
Figure 1 Eighty patients were enrolled, of whom 76 were received S-1 treatment. The treatment completion rates were 49.4% [95% confidential interval (CI), 32.8 to 65.9%] in group A and 52.1 % (95%CI, 35.5 to 68.6%) in group B (P = 0.4). The relative dose intensities were 40.4% (95%CI, 20.3 to 60.5%) in group A and 53.5% (95%CI, 37.7 to 69.3%) in group B (P = 0.4). There were no treatment-related deaths. Patients with grade 3/4 toxicities were significantly more frequent in group A (40.5%) than group B (15.4%, P = 0.02). The 2-year relapse-free survival rates were 97.5% in group A and 92.5% in group B, and the 2-year overall survival rates were 100% in both groups.
Two-week oral administration of S-1 followed by one week rest for one year may be more feasible for adjuvant chemotherapy in patients with completely-resected stage IA (T diameter, 2 to 3 cm) NSCLC.